Gut commensal
Animals
Ascomycota
Bacteroidetes
/ drug effects
Diabetes Mellitus, Type 2
/ prevention & control
Diet, High-Fat
Fecal Microbiota Transplantation
Fungal Polysaccharides
/ pharmacology
Gastrointestinal Microbiome
/ drug effects
Insulin Resistance
Male
Mice
Mice, Inbred C57BL
Molecular Weight
Obesity
/ prevention & control
Prebiotics
Symbiosis
colonic microflora
diabetes mellitus
nutrition
obesity
prebiotic
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
13
10
2017
revised:
22
06
2018
accepted:
22
06
2018
pubmed:
17
7
2018
medline:
19
1
2019
entrez:
16
7
2018
Statut:
ppublish
Résumé
The medicinal fungus High-fat diet (HFD)-fed mice were treated with HSM or fractions containing polysaccharides of different molecular weights. The effects of HSM and polysaccharides on the gut microbiota were assessed by horizontal faecal microbiota transplantation (FMT), antibiotic treatment and 16S rDNA-based microbiota analysis. Fraction H1 containing high-molecular weight polysaccharides (>300 kDa) considerably reduced body weight gain (∼50% reduction) and metabolic disorders in HFD-fed mice. These effects were associated with increased expression of thermogenesis protein markers in adipose tissues, enhanced gut integrity, reduced intestinal and systemic inflammation and improved insulin sensitivity and lipid metabolism. Gut microbiota analysis revealed that H1 polysaccharides selectively promoted the growth of HSM polysaccharides and the gut bacterium
Identifiants
pubmed: 30007918
pii: gutjnl-2017-315458
doi: 10.1136/gutjnl-2017-315458
doi:
Substances chimiques
Fungal Polysaccharides
0
Prebiotics
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
248-262Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: Y-FK is President of Chang Gung Biotechnology Corporation. JDY is Chairman of the Board of Chang Gung Biotechnology Corporation. The authors own patents related to the preparation and use of medicinal fungi and probiotics.